Stock BIXT BIOXYTRAN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Bioxytran, Inc.

Equities

BIXT

US09075D1028

Delayed OTC Markets
Other stock markets
 08:02:49 14/05/2024 pm IST 		5-day change 1st Jan Change
0.1243 USD +8.09% Intraday chart for Bioxytran, Inc. +15.63% -17.13%
19/04 Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
19/04 Bioxytran, Inc. Announces Board Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bioxytran : Change in Certifying Accountants - Form 8-K
PU
Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Bioxytran, Inc. Announces Board Changes
CI
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
AQ
Bioxytran, Inc. Announces Preprint of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist
CI
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
AQ
Bioxytran, Inc.'S Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for Covid-19
CI
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
AQ
Bioxytran Interview at the Emerging Growth Conference
AQ
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
AQ
Bioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patients
AQ
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
AQ
Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M
CI
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
AQ
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
AQ
Bioxytran, Inc. Initiates A Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID 19 Patients
CI
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIXT Stock
  4. News Bioxytran, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW